STOCK TITAN

Elray Exercises Warrants; 1.32M ETHZilla Shares Issued, Repurchase Agreement Announced

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Amendment No. 2 to Schedule 13D discloses that Anthony Brian Goodman and Elray Resources, Inc. hold a shared beneficial position in ETHZilla Corporation common stock after a cashless exercise of warrants. Elray exercised warrants on July 27, 2025, resulting in issuance of 1,320,000 shares on July 28, 2025. Elray sold portions of those shares on August 7, 8 and 11, 2025, totaling 1,317,?—the filing lists sales of 135,257, 777,595 and 405,148 shares at weighted average prices of $3.56, $3.18 and $3.17 respectively. The parties earlier entered a Settlement and Mutual Release Agreement where the company agreed to repurchase 1,318,000 shares for $1.0 million in staged payments; those shares are subject to a Voting Agreement and an irrevocable proxy in favor of the CEO through April 28, 2026.

Positive

  • Structured repurchase: The $1.0 million settlement provides a clear mechanism for the company to retire 1,318,000 shares upon payment, potentially reducing outstanding shares if completed
  • Voting alignment: A Voting Agreement and an irrevocable proxy in favor of the CEO ensure Elray's votes follow the board’s recommendations through April 28, 2026, supporting governance stability

Negative

  • Secondary selling: Elray sold shares totaling 1,318,000 across August 7, 8 and 11, 2025, indicating accelerated disposition of newly issued shares
  • Contingent cancellation: 1,318,000 shares remain subject to escrow and tranche-based cancellation tied to future payments, leaving share capital contingent until payments are made

Insights

TL;DR: A small, non-controlling position was created via cashless warrant exercise, followed by substantial secondary selling and a settlement-driven repurchase path.

The filing documents a cashless exercise that generated 1,320,000 shares and subsequent open-market sales across three dates, indicating partial monetization of the position. The prior Settlement and Mutual Release Agreement obligates the issuer to repurchase 1,318,000 shares for $1.0 million in tranches, and includes a Voting Agreement plus an irrevocable proxy to the CEO until April 28, 2026. Collectively, these arrangements reduce the reporting persons' economic and voting stakes in practice and provide the company with a structured path to retire shares. For investors, the disclosure is operationally important but not materially dilutive at the company-wide level given the reported <1% stake.

TL;DR: Governance controls are notable—shares subject to repurchase, a voting agreement, and an irrevocable proxy limit independent influence.

The Voting Agreement and irrevocable proxy granted to the CEO for the Company's benefit effectively aligns Elray's votes with the board through April 28, 2026, reducing the likelihood of activist action by the reporting persons. The escrowed stock powers and staged cancellations tied to settlement payments create conditional extinguishment of shares rather than immediate cancellation. These mechanisms protect the issuer’s governance stability during the repayment window but leave outstanding contingent rights until payments are completed.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
(8),(10),(11),(13) Includes 1,318,000 shares of Common Stock that are expected to be repurchased by the Issuer following the date of this filing pursuant to the terms of that certain Settlement and Release Agreement dated and effective April 23, 2024, by and between the Issuer, Elray Resources, Inc. and Luxor Capital, LLC, as discussed in greater detail below, which are also subject to the voting agreement, discussed below. (13) * Less than 1%. Based on 154,032,084 shares of Common Stock of the Company (as defined below) outstanding as of August 4, 2025, as set forth in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on the same date.


SCHEDULE 13D




Comment for Type of Reporting Person:
(8),(10),(11),(13) Includes 1,318,000 shares of Common Stock that are expected to be repurchased by the Issuer following the date of this filing pursuant to the terms of that certain Settlement and Release Agreement dated and effective April 23, 2024, by and between the Issuer, Elray Resources, Inc. and Luxor Capital, LLC, as discussed in greater detail below, which are also subject to the voting agreement, discussed below. (13) * Less than 1%. Based on 154,032,084 shares of Common Stock of the Company (as defined below) outstanding as of August 4, 2025, as set forth in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on the same date.


SCHEDULE 13D


Anthony Brian Goodman
Signature:/s/ Anthony Brian Goodman
Name/Title:Anthony Brian Goodman
Date:08/18/2025
Elray Resources, Inc.
Signature:/s/ Anthony Brian Goodman
Name/Title:Chief Executive Officer
Date:08/18/2025

FAQ

What shares did Elray acquire and when?

Elray exercised warrants on July 27, 2025 and was issued 1,320,000 shares of ETHZilla common stock on July 28, 2025.

Did Elray sell any ETHZilla (symbol: ATNFW) shares after issuance?

Yes. Elray sold 135,257 shares on August 7, 2025 (weighted avg $3.56), 777,595 shares on August 8, 2025 (weighted avg $3.18), and 405,148 shares on August 11, 2025 (weighted avg $3.17).

What is the Settlement and Mutual Release Agreement?

Under the April 28, 2025 settlement, the company agreed to acquire 1,318,000 shares from Elray for an aggregate $1,000,000 payable as $350,000 immediately and $650,000 from future capital raises by April 28, 2026.

Are the reporting persons able to vote the shares independently?

No. Elray agreed to a Voting Agreement to vote shares with the board’s recommendations through April 28, 2026, and granted an irrevocable proxy to the CEO solely for the company’s benefit.

Do the reporting persons hold a material percentage of the company?

No. The filing states their aggregate holding represents less than 1% of outstanding common stock based on a 154,032,084 share base.
180 Life Sciences Corp

NASDAQ:ATNFW

ATNFW Rankings

ATNFW Latest News

ATNFW Latest SEC Filings

ATNFW Stock Data

5.19M
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO